Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-18
2008-10-14
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S368000
Reexamination Certificate
active
07435738
ABSTRACT:
The invention relates to a stable polymorphic form of the compound 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2 (3H)-benzoxazolone monomethanesulfonate (INNM bifeprunox mesylate), a method for the preparation of said polymorphic form and its use in pharmaceutical products, especially in pharmaceutical products for the treatment of psychotic disorders and Parkinson's disease.
REFERENCES:
patent: 2004/0077631 (2004-04-01), Van Aar et al.
patent: 2005/0234389 (2005-10-01), Bouwstra et al.
patent: 0 908 458 (1999-04-01), None
patent: 0 189 612 (2006-08-01), None
patent: WO 97/36893 (1997-10-01), None
patent: WO 00/29397 (2000-05-01), None
patent: WO 01/74365 (2001-10-01), None
patent: WO 02/066449 (2002-08-01), None
patent: WO 2006/032202 (2006-03-01), None
patent: WO2006/087369 (2006-08-01), None
patent: WO 2007/02341 (2007-03-01), None
U.S. Appl. No. 11/727,173, filed Feb. 2007, Eijgendaal et al.
U.S. Appl. No. 10/920,361, Eijgendaal et al.
Haleblian et al., “Pharmaceutical Applications of Polymorphism,”Journal of Pharmaceutical Sciences, 58(8):911-929 (1969).
European Search Report for EP 03 10 2573.
Copending U.S. Appl. No. 10/920,361, filed Aug. 18, 2004.
Copending U.S. Appl. No. 11/354,652, filed Feb. 16, 2006.
“Bifeprunox - Atypical Antipsychotic Drug,” Drug Development Technology, pp. 1-3, 2007, www.drugdevelopment-technology.com/projects/bifeprunox/.
“Solvay Announces New Drug Plans for Schizophrenia,” Schizophrenia Daily New Blog,pp. 1-4 (2004), www.schizophrenia.com/sznews/archives/00573.html.
(XP-001061442) Johnston, L.C. et al., “134P: The Novel Dopamine DA Receptor Partial Agonist, SLV-308, Reverses Motor Disability in MPTO-Lesioned Common Marmosets (CALLITHRIXJACCHUS),” British Journal of Pharmacology, vol. 133, No. 2 (2001).
(XP-001061489) Feenstra, R. et al., “Antiparkinsonian Antidepressant Anxiolytic Dopame D2 Partial Agonists 5-HT1A Agonist,” Drugs of the Future, vol., 26, No. 2, 2001, pp. 128-132.
(XP-001197381) McCreary, et al., “SLV308: A Novel Antiparkinsonian Agent With Antidepressant and Anxiolytic Efficacy,” Abstracts of the Society for Neuroscience (2001).
(XP-002412435) Hesselink, M. et al., “308, A Molecule Combining Potent Partial Dopamine b2 Receptor Agonism with Serotonin 5-HT1A Receptor Agonism: In vitro and in vivo neuro-chemistry,” 31st Annual Meeting of the Society for Neuroscience (2001).
(XP-002412436) Johnston, L.C. et al., “SLV308: Antiparkinsonian Effects in the MPTP-Treated Common Marmoset (Callithrix jacchus),” 31st Annual Meeting of the Society for Neuroscience (2001).
(XP-002412438) Long Act Sustained-Relase Formulations for Treating Parkinson's Disease, Comprise a Dopamine Receptor Agonist and Biodegradable Pharmaceutical Polymer Excipient for Injection Transplant, Corresponds to WO 2006/032202.
(XP008033520) Wolf, William A., “SLV-308 Solvay,” Current Opinion in Investigational Drugs, vol. 4, No. 7, 2003, pp. 878-882.
Allen, et al. “A Review of Clinical and Pathophysiologic Features,” Journal of Clinical Neurophysiology, vol. 18, No. 2, 2001, pp. 128-147.
Allen, et al., “Augmentation of the Restless Legs Syndrome With Carbidopa/Levedopa,” Sleep, vol. 19, No. 3, 1996, pp. 205-213.
Bara-Jimenez et al., “Effects of Serotonin 5-HT1A Agonist in Advanced Parkinson's Disease,” Movement Disorders, vol. 20, No. 8, 2005, pp. 932-936.
Bennett, et al., “Pramipexole - A new dopamine agonist for the treatment of Parkinson's Disease,” Journal of Neurological Sciences, vol. 163, 1999, pp. 25-31.
Berendsen, et al., “Selective Activation of 5HT1A Receptors Induces Lower Lip Retraction in the Rat,”Pharmacology Biochemistry & Behavior, vol. 33, pp. 821-827, 1989.
Bibbiani, et al., “Serotonin 5-HT1A Agonist Improves Motor Complications In Rodent and Primate Parkinsonian Models,” Neurology, vol. 57, 2001, pp. 1829-1834.
Bickel, M.H., “The Pharmacology and Biochemistry of N-Oxides,” Pharmacological Reviews, vol. 21, No. 4, pp. 325-355, 1969.
Blandini, et al., “Functional Changes of the Basal Ganglia Circuitry in Parkinson's Disease,” Progress in Neurobiology, vol. 62, 2000, pp. 63-88.
Chesson, et al., “Practice Parameters for the Treatment of the Restless Legs Syndrome and Periodic Limb Movement Disorder,” Sleep, vol. 22, No. 7, 1999, pp. 961-968.
Christoffersen, et al., “Reversal of Haloperiodol-Induced Extrapyramidal Side Effects in Cebus Monkeys by 8-Hydroxy-2-(di-n-propylamino)tetralin and Enantiomers,” Neuropsychopharmacology, vol. 18, No. 5, 1998, pp. 399-402.
Costall et al., “Differential actions of typical and atypical neuroleptic agents on two behavioural effects of apomorphine in the mouse,” Proceedings of the B.P.S., pp. 381-381, 1978.
Creese et al., “3H-Spiroperidol Labels Dopamine Receptors in Pituitary and Brain,” European Journal of Pharmacology, 46, pp. 377-381, 1977.
Earley, et al., “Movements During Sleep: Pergolide and Carbidopa/Levedopa Treatment of the Restless Legs Syndrome and Periodic Leg Movements in Sleep in a Consecutive Series of Patients,” Sleep, vol. 19, No. 10, 1996, 801-810.
Feenstra, et al., “New 1-Aryl-4-(biarylmethylene) piperazines as Potential Atypical Antipsychotics Sharing Dopamine Dz-Receptor and Serotonin 5-HT1A-Receptor Affinities,” Bioorganic & Medicinal Chemistry Letters, vol. 11, 2001, pp. 2345-2349.
Feenstra, et al., “New Approaches for Psychosis Treatment: Design, Synthesis and SAR of Ligands Binding to Dopamine-D2- and Serotonin 5-HT1A Receptors,” Drugs of the Future, vol. 27, Suppl. A, p. 226 (P237), XVIIth International Symposium on Medicinal Chemistry (2002).
Fleischhacker, “Clozapine: A Comparison With Other Novel Antipsychotics,” J. Clin Psychiatry, vol. 60, No. 12, 1999, pp. 30-34.
Gozlan, et al., “Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT,” Nature, vol. 305, pp. 140-142, 1983.
Hening, et al., “Dyskinesias While Awake and Periodice Movements In Sleep In Restless Legs Syndrome: Treatment with Opioids,” Neurology, vol. 36, 1986, pp. 1363-1366.
Hening, et al., “The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder,” Sleep, vol. 22, No. 7, 1999, pp. 970-999.
Hesselink, M.B., et al., “P2151” “DU127090, SLV308 and SLV318: Characterization of a Chemically Related Class of Partial Dopamine Agonists with Varying Degrees of 5-HT1A Agonism,” EFNS European Journal of Neurology, vol. 10, (Suppl. 1), 2003, pp. 125-204.
Hornykiewicz, Oleh, “Dopamine (3-Htdroxytyramine) and BRain Function,” Pharmaceutical Reviews, vol. 18, No. 2, 1966, pp. 925-964.
Jankovic, “Natural Course and Limitations of Levodopa Therapy,” Neurology, Vol. 43, No. 2, Supplement 1, 1993, pp. S1-14 thru S1-17.
Jenner, Peter, “Pharmacology of Dopamine Agonists in the Treatment of Parkinson's Disease,” Neurology vol. 58 (Suppl. 1), 2002, pp. S1-S8.
Johnston, et al., P2158, “Association between Instrinic Activity and the Antiparkinsonian Effects of a Novel Dopaime D2 Agonist series in the 1-methyl-4phenyl-1,2,36-tetrahydeopyridine Treated Primate Model of Parkinson's Disease,” EFNS European Journal of Neurology, vol. 10 (Suppl. 1), 2003, pp. 169-170.
Jost, et al., “Efficacy and tolerability of Stalevo® in Patients with Parkinson's Disease Experiencing Wearing-off,” Akt Neurol, vol. 32, Supplement 6, 2005, pp. S318-S325 (XP009074453).
Kannari, et al., “Tandospirone Citrate, sselective 5-HT1A Agonist, Alleviates L-DOPA-Induced Dyskinesia in Patients with Parkinson's Disease,” BRAIN and NERVE, vol. 54, Nov. 2, 2002, pp. 133-137.
Kim, et al., “Risperidone Dosing Pattern and Clinical Outcome in Psychosis: An Analysis of 1713 Cases,” J. Clin Psychiatry, vol. 66,
Eijgendaal Irene
Klein Gerrit
Terhorst-Van Amstel Maria J. L.
Zwier Klaas
Finnegan
Sackey Ebenezer
Solvay Pharmaceuticals, Inc.
Wilson James O.
LandOfFree
Stable crystalline form of bifeprunox mesylate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable crystalline form of bifeprunox mesylate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable crystalline form of bifeprunox mesylate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988384